ChemRar Group of Companies and Pharmasyntez Group of Companies have officially entered into a license agreement to collaborate on the development and release of a groundbreaking medication to combat emerging strains of influenza. The initial clinical trials, which aim to assess the safety and tolerability of the experimental medication, have already been scheduled for the conclusion of the second quarter in 2023.
The drug candidate developed by ChemRar has demonstrated high efficacy and safety in preclinical studies. The initial clinical trials to assess the safety and tolerability of the experimental medication are already set for the conclusion of the second quarter in 2023. Further research will be carried out jointly by the Pharmasyntez team.